Magellan Health, Inc. MGLN
Magellan destroyed $700M of value through failed acquisitions and three 2018 guidance cuts; Starboard's six-director slate will overhaul the board and run a parallel sale process at peer multiples.
Thesis
Magellan Health has trailed the S&P 500 Managed Care Index by 978% over the past decade, the result of a 2013-2018 acquisition spree that deployed over $1 billion yet destroyed more than $700 million of shareholder value while segment profit margins collapsed from 7.3% to 3.8%. CEO Barry Smith's expansion into Medicaid forced subscale Magellan to compete against UnitedHealth, Anthem, and Centene, culminating in three consecutive 2018 EPS guidance cuts that halved the share price from $111 to $59. Starboard, holding 9.8%, is nominating six directors — including former Magellan turnaround CEO Steven Shulman — for the 2019 Annual Meeting to overhaul the board, drive a credible cost-cutting plan beyond management's inadequate 2.0% net-margin target, and concurrently explore strategic alternatives including a sale at the 12.9x EBITDA peer multiple versus Magellan's current 8.0x.
SCQA
Magellan Health is a $7.4B-revenue specialty managed care and PBM operator in an industry with strong secular tailwinds, serving behavioral health, Medicaid managed care, and pharmacy benefit segments.
An aggressive acquisition strategy and Medicaid expansion against scaled rivals destroyed over $700M of shareholder value, halved segment margins to 3.8%, and triggered three consecutive 2018 EPS guidance cuts that collapsed the stock 47%.
Elect Starboard's six-nominee slate at the 2019 Annual Meeting to reconstitute the board, drive a credible operational turnaround beyond management's inadequate 2.0% margin target, and run a parallel review of strategic alternatives including a full sale.
Precedent managed care and PBM transactions cleared at an average 12.9x EBITDA versus Magellan's 8.0x, implying a substantial sale premium; closing the peer net-margin gap to 3.6% would similarly re-rate the standalone equity.
The three reasons
- 1
10-year TSR underperformed S&P 500 Managed Care Index by 978% and proxy peer group by 761%
- 2
>$1B in acquisitions since 2013 destroyed >$700M of value as segment margins halved from 7.3% to 3.8%
- 3
Precedent managed care/PBM deals cleared 12.9x EBITDA versus Magellan's 8.0x — sale would unlock substantial premium
Primary demands
- Elect Starboard's slate of six director nominees at the 2019 Annual Meeting
- Reconstitute the board with a majority of new independent directors
- Initiate a formal review of strategic alternatives, including a sale of the whole company or separation of assets
- Drive a credible operational turnaround that takes net margins materially above management's inadequate 2.0% long-term target
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Aetna acquired by CVS Health (12.1x EBITDA, Dec 2017)
- Fidelis Care acquired by Centene (9.4x, Sep 2017)
- Meridian acquired by WellCare (17.7x, May 2018)
- Universal American acquired by WellCare (14.1x, Nov 2016)
- Express Scripts acquired by Cigna (12.5x, Mar 2018)
- Genoa Healthcare acquired by UnitedHealth/OptumRx (Oct 2018)
- LDI Integrated Pharmacy Services acquired by Diplomat Pharmacy (13.2x, Nov 2017)
- eviCore Healthcare acquired by Express Scripts (13.1x, Oct 2017)
- Steven Shulman's prior Magellan turnaround out of bankruptcy (2002-2008)
- Health Management Associates proxy contest and sale to Community Health Systems (Shulman)
- Prudential Healthcare turnaround and sale to Aetna (Shulman)
- Symantec operational turnaround (Peter Feld directorship)
Notable slides (5)
Notes
Filed as Exhibit 1 to a DFAN14A proxy solicitation. Classic Starboard playbook: TSR underperformance table, value-destruction waterfall, peer-gap margin chart, precedent-transactions table, and CEO/CFO quotes used to lock management into their own admission of a 'bloated cost structure'. Notable rhetorical move: nominating Steven Shulman, the former Magellan CEO who led the company out of bankruptcy in 2002-2008, as a 'returning savior' nominee. Letter format (Times Roman body) with embedded institutional-blue charts and callout boxes — functional but not stealable design craft. Six-nominee slate vs. five open seats explicitly flagged as a negotiating posture (Starboard signals it would settle for one of its own + four independents).